Gefitinib in Non Small Cell Lung Cancer

Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	BioMed research international 2011, Vol.2011 (2011), p.1-14
Hauptverfasser:	Perrone, Francesco, Morabito, Alessandro, Normanno, Nicola, Rocco, Gaetano, Di Maio, Massimo, De Feo, Gianfranco, Bryce, Jane, Giordano, Pasqualina, Carillio, Guido, Montanino, Agnese, Daniele, Gennaro, Sandomenico, Claudia, Costanzo, Raffaele, Piccirillo, Maria Carmela
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!